Halozyme Therapeutics, Inc. revenue
Halozyme Therapeutics, Inc.'s revenue was $1.40bn in fiscal 2025, up 37.6% on the year before. Since fiscal 2009 ($13.7m) it has grown at a compound 33.5% a year. Over the last twelve months it was $1.66bn.
Revenue history
| Fiscal year | 2009Dec 2009 | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 14 | 14 | 56 | 42 | 55 | 75 | 135 | 147 | 317 | 152 | 196 | 268 | 443 | 660 | 829 | 1,015 | 1,397 | 1,664 |
| Growth on the year before | — | −0.3% | +311.7% | −24.5% | +29.5% | +37.5% | +79.3% | +8.6% | +115.8% | −52.0% | +29.1% | +36.5% | +65.7% | +48.9% | +25.6% | +22.4% | +37.6% | — |
| Gross profit | — | — | — | — | — | — | — | — | 285 | 142 | 150 | 224 | 362 | 521 | 637 | 856 | 1,168 | 1,371 |
Where the revenue comes from
| Line of business | Revenue | YoY |
|---|---|---|
| Royalty | $868M | ▲ 52.0% |
| Products | $376M | ▲ 24.0% |
| Proprietary Products Sales | $195M | ▲ 16.8% |
| Collaborative Agreements | $152M | ▲ 8.2% |
| Bulk R Hu PH20 | $133M | ▲ 54.1% |
| Salesbasedmilestone | $70M | ▲ 133.3% |
| Device Partnered Products | $48.8M | ▼ 3.4% |
| Event Based Development and Regulatory Milestone and Other Fees | $47M | ▼ 35.2% |
| Upfront Fees | $18.5M | ▼ 31.6% |
| Device Licensing and Development | $16.9M | ▲ 48.6% |
These categories overlap or exclude eliminations, so shares aren't shown.
From Halozyme Therapeutics, Inc.'s 10-K filed February 17, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Halozyme Therapeutics, Inc. | $1.66bn | 41.2% | 29.1% |
| Alkermes plc. | $1.67bn | 10.8% | 4.5% |
| Insmed Inc | $1.52bn | 240.0% | 75.6% |
| Madrigal Pharmaceuticals, Inc. | $1.28bn | 149.0% | — |
| Lakefront Biotherapeutics NV | $1.26bn | 321.6% | — |
| Moderna | $2.23bn | -27.6% | -40.6% |
Compare with peers
- Alkermes plc. revenue
- Insmed Inc revenue
- Madrigal Pharmaceuticals, Inc. revenue
- Lakefront Biotherapeutics NV revenue
- Moderna revenue
Head to head: ALKS vs HALOHALO vs INSMHALO vs MDGL
More: Biotechnology stocks compared, Health Care sector, rankings of US companies